AGL Stock Recent News

NEW YORK , Aug. 16, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  agilon health, Inc. ("agilon" or the "Company") (NYSE: AGL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

AGL Energy Limited (OTCPK:AGLNF) Q4 2025 Earnings Conference Call August 12, 2025 9:00 PM ET Company Participants Damien Nicks - MD, CEO & Director Gary Brown - Chief Financial Officer James Thompson - Head of Investor Relations Jo Egan - Chief Customer Officer Markus Brokhof - Chief Operating Officer Conference Call Participants Anthony Moulder - Jefferies LLC, Research Division Dale Johannes Koenders - Barrenjoey Markets Pty Limited, Research Division Gordon Alexander Ramsay - RBC Capital Markets, Research Division Henry Meyer - Goldman Sachs Group, Inc., Research Division Ian Myles - Macquarie Research Robert Koh - Morgan Stanley, Research Division Tom Allen - UBS Investment Bank, Research Division James Thompson Thank you for standing by, and welcome to the AGL Energy Full Year Results Briefing Conference Call. [Operator Instructions] I would now like to hand over the conference to Managing Director and Chief Executive Officer, Mr.

LOS ANGELES , Aug. 12, 2025 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of agilon health, inc. ("Agilon" or "the Company") (NYSE: AGL) for violations of the securities laws.

Bragar Eagel & Squire, P.C. Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Agilon (AGL) To Contact Him Directly To Discuss Their Options

NEW YORK , Aug. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of agilon health, Inc. ("agilon" or the "Company") (NYSE: AGL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  agilon health, Inc. (“agilon” or the “Company”) (NYSE: AGL).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK , Aug. 6, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of agilon health, Inc. ("agilon" or the "Company") (NYSE: AGL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

agilon health, inc. (NYSE:AGL ) Q2 2025 Earnings Conference Call August 5, 2025 5:30 PM ET Company Participants Evan Smith - Corporate Participant Jeffrey Alan Schwaneke - Executive VP & CFO Ronald Allan Williams - Chairman of the Board Conference Call Participants Andrew Mok - Barclays Bank PLC, Research Division Craig Jones - BofA Securities, Research Division Eduardo Enrique Ron - Truist Securities, Inc., Research Division Elizabeth Hammell Anderson - Evercore ISI Institutional Equities, Research Division George Robert Hill - Deutsche Bank AG, Research Division Jack Garner Slevin - Jefferies LLC, Research Division Jenny Shen - BTIG, LLC, Research Division Justin Lake - Wolfe Research, LLC Lance Arthur Wilkes - Sanford C.

Citi downgraded Agilon Health to Neutral from Buy with a price target of $1, down from $3 after its Q2 results and pulled guidance. The company's Q2 earnings miss was largely driven by limited risk scoring visibility, concentrated in two payors, the analyst tells investors in a research note. Citi adds that the firm had caught-up with the management this afternoon, noting that while the conversation offered confidence that the issues AGL experienced are not structural, AGL's visibility remains limited, which will keep the shares range-bound in the near term.

SAN DIEGO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP, a shareholder rights law firm, announces that it is investigating potential claims on behalf of investors of Agilon Health, Inc. (NYSE: AGL) regarding possible violations of federal securities laws.